Dublin, Feb. 17, 2016 (GLOBE NEWSWIRE) -- Research and Markets (http://www.researchandmarkets.com/research/m4zcrj/personalized) has announced the addition of the "Personalized Medicine, Targeted Therapeutics and Companion Diagnostic Market to 2019 - Strategic Analysis of Industry Trends, Technologies, Participants and Environment" report to their offering.

This market is made up of companion diagnostics and targeted therapeutics and is dominated by oncology, cardiovascular and infectious disease targeted treatment and diagnostics. The report Personalized Medicine, Targeted Therapeutics and Companion Diagnostic Market: Strategic Analysis of Industry Trends, Technologies, Participants, and Environment has already been procured by 21 of the top 25 Pharma companies globally. This newly published edition, is a revolutionary insight into the vertical growing market of personalized healthcare globally.

The author forecasts that the total personalised targeted therapeutic market, for all indications, will grow at a CAGR of 6.47% over the next five years. Strong vertical growth in the companion diagnostic segment however will see a CAGR of 23.71% to 2020, mainly coming from oncology, cardiovascular and infectious disease (HIV/HCV) tests. Advancing technologies within the liquid biopsy market is also driving the market and will see strategic growth over the next five years with a CAGR of 20.6%. The two segments of the liquid biopsy market are tumor cell enrichment products and tumor cell detection technologies.

Individualized, targeted or personalized medicine aims to increase the efficacy of therapeutics via genetic testing and companion diagnostics. Personalized therapeutics and associated companion diagnostics are more specific and effective thereby giving pharma/biotech companies a significant advantage to recuperate R&D costs. Personalized medicine reduces the frequency of adverse drug reactions and therefore has a dramatic impact on health economics. Developmental and diagnostic companies benefit from lower discovery and commercialization costs and more specific market subtypes.

Updates on the personalized medicine, targeted therapeutic and companion diagnostic space have been included in this latest edition to include cutting edge material from international conferences, workshops and symposia.

Key Topics Covered:

1.0 Executive Summary

2.0 Introduction and Background

3.0 Personalized Medicine Targeted Therapeutics and Associated Companion Diagnostics

4.0 Personalized Medicine and Integration into the Healthcare System

5.0 Private and Public Funding and Personalized Medicine Reimbursement

6.0 European Personalized Medicine Market - Payments and Investment

7.0 Personalized Medicine -Business Model Analysis

8.0 Personalized Medicine Main Industry Players

9.0 Personalized Medicine Market Analysis

10.0 Strengths and Advantages of Personalized Medicine

11.0 Restraints of the Personalized Medicine Market

12.0 Personalized Medicine and Regulatory Policies

13.0 Final Summary and Future Perspectives

14.0 Interviews with Key Opinion Leaders

Companies Mentioned

- 23andMe
- Abbott Laboratories
- Abbott Molecular Inc.
- Admera Health (GENEWIZ)
- Atossa Genetics
- Becton Dickenson
- bioMerieux
- BristolMyersSquibb
- Cancer Genetics
- Danaher (Leica Biosystems)
- deCode Genetics (Amgen)
- Foundation Medicine
- EDP Biotech
- Eli Lilly
- ELDA BioTech
- Eisai
- Genelex
- GlaxoSmithKline
- Human Longevity Inc (Cypher Genomics)
- HalioDx
- Ikonisys
- Illumina
- InterGenetics
- Johnson & Johnson
- LabCorp
- Merck
- Pfizer
- Qiagen
- Roche Molecular Diagnostics
- Sanofi
- SensiGen
- Siemens Healthcare Diagnostics
- Takeda
- Thermo Fisher Scientific
- Transgenomic

For more information visit http://www.researchandmarkets.com/research/m4zcrj/personalized

CONTACT: Research and Markets
         Laura Wood, Senior Manager
         press@researchandmarkets.com

         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900

         U.S. Fax: 646-607-1907
         Fax (outside U.S.): +353-1-481-1716

         Sector: Genomics, Diagnostics, Genomics, In Vitro Diagnostics

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.